James Garner AKA JG, page-104

yes Capricors and a couple of others in this space always show a decline (or strange whimsical statistics like climbing stairs half a second faster across eg ten seconds).

But Capricor will be meeting with the FDA later this year to seek fast track approval, it will be interesting to watch how the FDA react here. Their phase 2B was much smaller than ours is so they had to continue on to phase 3 having about double our numbers in it currently from memory.

If the market is aware of us from a high level understanding they are perhaps just investing in CAP for the potential FDA approval. Because you wouldn't want to be invested in CAP or any other inflam drug when our results come out.

In other words wherever CAP go we should be multiples of them as we are the top tier (but yet to be placebo proven) drug in this space. Furthermore their drug is diluted by their Japanese owners. 150M USD also.